Limits...
RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale.

Inazawa T, Sakamoto K, Kohro T, Iijima R, Kitazawa T, Hirano T, Kawamura M, Tagami M, Tanaka A, Mori Y, Yamazaki T, Shiba T, RESEARCH Study Gro - Lipids Health Dis (2013)

Bottom Line: In this study we seek to demonstrate the superior effect of ezetimibe in combination with strong statins to reduce LDL-C in Japanese patients suffering from both T2DM and hyper LDL-cholesterolemia.We could successfully create randomized (gender, age, LDL-C, HbA1c, etc.) two groups except for slight differences in apolipoprotein-B and sd-LDL.RESEARCH is the first prospective, parallel-group, multicenter study comparing a double dose of strong statin with ezetimibe plus strong statin for T2DM patients.

View Article: PubMed Central - HTML - PubMed

Affiliation: Toho University Ohashi Medical center, Tokyo, Japan. teruo.shiba@med.toho-u.ac.jp.

ABSTRACT

Aims: Hypercholesterolemia coexisting with diabetes still requires clinical intervention to manage the high risk of cardiovascular disease it poses. No second-step strategy is established, however, for cases where strong statins fail to bring cholesterol down to target levels. In this study we seek to demonstrate the superior effect of ezetimibe in combination with strong statins to reduce LDL-C in Japanese patients suffering from both T2DM and hyper LDL-cholesterolemia.

Methods: T2DM outpatients (109 patients from 16 institutes) who failed to achieve the target LDL-C value were recruited and randomly assigned to two groups, a double-dose-statin group and ezetimibe-plus-statin group. Follow-ups were scheduled at 0, 12, 26, and 52 weeks. The primary endpoint was the percentage change in the level of LDL-C from baseline to 12 weeks.

Interim results: We could successfully create randomized (gender, age, LDL-C, HbA1c, etc.) two groups except for slight differences in apolipoprotein-B and sd-LDL.

Conclusions: RESEARCH is the first prospective, parallel-group, multicenter study comparing a double dose of strong statin with ezetimibe plus strong statin for T2DM patients. The RESEARCH study will provide reliable evidence with which to establish a clinical strategy for diabetics who fail to achieve the target LDL-C value.

Show MeSH

Related in: MedlinePlus

Design scheme for the RESEARCH study. The numbers of patients appear inside brackets. T2DM: type 2 diabetes mellitus.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3852628&req=5

Figure 1: Design scheme for the RESEARCH study. The numbers of patients appear inside brackets. T2DM: type 2 diabetes mellitus.

Mentions: Patients who provided informed consent were randomly assigned to two groups, a double-dose-statin (DS) group and ezetimibe-plus-statin (ES) group. The patients were randomized through a system for online central registration. To reduce heterogeneity between groups, dynamic allocation was adopted using age and gender as assignment factors. The results of the randomization were open to both the patients and doctors.


RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale.

Inazawa T, Sakamoto K, Kohro T, Iijima R, Kitazawa T, Hirano T, Kawamura M, Tagami M, Tanaka A, Mori Y, Yamazaki T, Shiba T, RESEARCH Study Gro - Lipids Health Dis (2013)

Design scheme for the RESEARCH study. The numbers of patients appear inside brackets. T2DM: type 2 diabetes mellitus.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3852628&req=5

Figure 1: Design scheme for the RESEARCH study. The numbers of patients appear inside brackets. T2DM: type 2 diabetes mellitus.
Mentions: Patients who provided informed consent were randomly assigned to two groups, a double-dose-statin (DS) group and ezetimibe-plus-statin (ES) group. The patients were randomized through a system for online central registration. To reduce heterogeneity between groups, dynamic allocation was adopted using age and gender as assignment factors. The results of the randomization were open to both the patients and doctors.

Bottom Line: In this study we seek to demonstrate the superior effect of ezetimibe in combination with strong statins to reduce LDL-C in Japanese patients suffering from both T2DM and hyper LDL-cholesterolemia.We could successfully create randomized (gender, age, LDL-C, HbA1c, etc.) two groups except for slight differences in apolipoprotein-B and sd-LDL.RESEARCH is the first prospective, parallel-group, multicenter study comparing a double dose of strong statin with ezetimibe plus strong statin for T2DM patients.

View Article: PubMed Central - HTML - PubMed

Affiliation: Toho University Ohashi Medical center, Tokyo, Japan. teruo.shiba@med.toho-u.ac.jp.

ABSTRACT

Aims: Hypercholesterolemia coexisting with diabetes still requires clinical intervention to manage the high risk of cardiovascular disease it poses. No second-step strategy is established, however, for cases where strong statins fail to bring cholesterol down to target levels. In this study we seek to demonstrate the superior effect of ezetimibe in combination with strong statins to reduce LDL-C in Japanese patients suffering from both T2DM and hyper LDL-cholesterolemia.

Methods: T2DM outpatients (109 patients from 16 institutes) who failed to achieve the target LDL-C value were recruited and randomly assigned to two groups, a double-dose-statin group and ezetimibe-plus-statin group. Follow-ups were scheduled at 0, 12, 26, and 52 weeks. The primary endpoint was the percentage change in the level of LDL-C from baseline to 12 weeks.

Interim results: We could successfully create randomized (gender, age, LDL-C, HbA1c, etc.) two groups except for slight differences in apolipoprotein-B and sd-LDL.

Conclusions: RESEARCH is the first prospective, parallel-group, multicenter study comparing a double dose of strong statin with ezetimibe plus strong statin for T2DM patients. The RESEARCH study will provide reliable evidence with which to establish a clinical strategy for diabetics who fail to achieve the target LDL-C value.

Show MeSH
Related in: MedlinePlus